Prospera Financial Services Inc Sells 777 Shares of Illumina, Inc. $ILMN

Prospera Financial Services Inc trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 12.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,608 shares of the life sciences company’s stock after selling 777 shares during the quarter. Prospera Financial Services Inc’s holdings in Illumina were worth $535,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ILMN. Rise Advisors LLC lifted its stake in shares of Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after buying an additional 224 shares in the last quarter. Cullen Frost Bankers Inc. bought a new position in Illumina in the 2nd quarter valued at about $41,000. NewSquare Capital LLC increased its holdings in Illumina by 604.9% during the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after purchasing an additional 369 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in shares of Illumina by 2,936.8% in the first quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock worth $46,000 after purchasing an additional 558 shares during the last quarter. Finally, Center for Financial Planning Inc. lifted its holdings in shares of Illumina by 42.4% in the second quarter. Center for Financial Planning Inc. now owns 588 shares of the life sciences company’s stock valued at $56,000 after purchasing an additional 175 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN opened at $120.67 on Friday. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $153.06. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The stock’s fifty day moving average price is $102.84 and its two-hundred day moving average price is $95.86. The firm has a market cap of $18.44 billion, a PE ratio of 15.27, a PEG ratio of 2.34 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.18. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm’s revenue for the quarter was up .4% on a year-over-year basis. During the same quarter last year, the firm posted $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Insider Transactions at Illumina

In related news, Director Scott Gottlieb bought 500 shares of the company’s stock in a transaction on Monday, November 3rd. The shares were purchased at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the transaction, the director directly owned 12,523 shares in the company, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 2.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ILMN. Robert W. Baird set a $109.00 price target on Illumina in a research report on Friday, October 31st. JPMorgan Chase & Co. boosted their price target on shares of Illumina from $100.00 to $105.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Cowen restated a “hold” rating on shares of Illumina in a research note on Friday, October 31st. Finally, Evercore ISI increased their price target on Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Five investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Illumina has an average rating of “Hold” and a consensus price target of $115.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.